Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to combat neurological disorders that affect hundreds of millions of people worldwide. The company's pipeline includes Lucid-MS, a patented new chemical entity for multiple sclerosis (MS), and unbuzzd, a dietary supplement designed to mitigate the effects of alcohol intoxication.
Multiple sclerosis is a debilitating disease affecting approximately 2.9 million people globally, with about one million cases in the United States. Existing therapies often fall short, leaving patients with limited options. Lucid-MS takes a fundamentally different approach from current treatments, and its phase 2 development is supported by an ongoing imaging collaboration with Massachusetts General Hospital, as detailed in the company's press release.
In addition to MS, Quantum BioPharma is addressing the acute cognitive and physiological impacts of alcohol consumption with unbuzzd. This proprietary dietary supplement is formulated to support alcohol metabolism and reduce hangover severity, targeting a common but underserved health concern.
The company's dual focus highlights its commitment to areas of high unmet need. For more information, please see the full terms of use and disclaimers at http://IBN.fm/Disclaimer. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this article involve risks and uncertainties, as described in the company's filings with the SEC. Undue reliance should not be placed on these statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
